Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00776178 · ClinicalTrials.gov registry record
Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 68
- Enrollment target
NCT00776178: Completed study, sponsored by National Cancer Institute (NCI).
NCT00776178 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 68 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00776178 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 68 participants
- Enrollment target
Study Summary
Background: * Bladder cancer often recurs after treatment and patient survival varies greatly. * More knowledge is needed about factors that can help identify patients who are at greater risk of disease recurrence and progression to minimize the need for screening and to help guide treatment. * The New England Study of Environment and Health (NESEH), conducted by the departments of health in Maine, New Hampshire and Vermont, the Dartmouth Medical School and the NIH, examined the relationship between health and environmental factors such as smoking, diet and water quality in New England. This study provides an opportunity to learn more about patients with bladder cancer. * Before launching a full-scale follow-up study on bladder cancer, it is necessary to determine the feasibility of obtaining needed follow-up information from patients enrolled in the NESEH. Objectives: -To determine the completeness and quality of information about treatment, recurrence, and progression that can be obtained for patients from their medical records. Eligibility: -Participants from the NESEH study who are residents of Maine and who were diagnosed with bladder cancer between 2001 and 2003. Design: * Determine the vital status of NESEH bladder cancer patients. * Select a sample of 40 living and 18 deceased patients. * Interview patients or their next of kin by telephone for about 30 to 45 minutes to update exposure information, obtain names and addresses of all hospitals and physicians they have seen since diagnosis, and obtain authorization to access medical records. * Obtain and abstract medical records.
Primary Outcome
Overall Survival
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2008-10-17 |
| Est. Completion | 2020-03-31 |
What the finished NCT00776178 record still lists
NCT00776178 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 68 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT00776178 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00776178 about?
NCT00776178 is a clinical study titled "Follow-Up of Bladder Cancer Patients From the New England Study of Environment and Health". Background: * Bladder cancer often recurs after treatment and patient survival varies greatly. * More knowledge is needed about factors that can help identify patients who are at greater risk of disease recurrence and progression to minimize the need for screening and to help guide treatment. * The...
What is the current status of trial NCT00776178?
This trial is currently completed. The enrollment target is 68 participants. The study started on 2008-10-17. Estimated completion is 2020-03-31.
Who is sponsoring clinical trial NCT00776178?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI